Navigation Links
Zosano Pharma, Inc. Announces Key Strategic Hire
Date:4/9/2013

FREMONT, Calif., April 9, 2013 /PRNewswire/-- Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, announced today that Chris Krueger has been appointed as the company's Chief Business Officer. In this position, Mr. Krueger will be responsible for the company's business development, legal, and investor relations activities.

"We are delighted to have Chris join our team. He brings extremely valuable and relevant healthcare industry experience to Zosano Pharma. His business development expertise and a track record of building successful businesses will be invaluable as we prepare to advance several of our drug candidates," commented Vikram Lamba, Zosano Chief Executive Officer.

Prior to joining Zosano Pharma, Mr. Krueger served as Senior Vice President and Chief Business Officer at Ardea Biosciences. In addition to several successful financings at Ardea, he completed a $407 million global partnership with Bayer HealthCare. Previously, Mr. Krueger served in senior executive roles at Protemix, Xencor, X-Ceptor Therapeutics and Aurora Biosciences. In his previous roles, he completed a broad range of transactions, including licensing, strategic alliances, mergers and acquisitions and equity and debt financings.  Earlier in his career, Mr. Krueger was a corporate lawyer at Cooley LLP.

"It's exciting for me to join the Zosano team as the company enters its next stage of corporate growth," said Mr. Krueger. "With its novel transdermal drug delivery system, Zosano is poised to develop therapeutic products through its own efforts and through strategic collaborations."

About Zosano Pharma

Zosano Pharma, Inc. is a private biopharmaceutical company and a pioneer in the field of drug delivery systems. Zosano is developing products using ZP Patch Technology, a novel transdermal delivery technology based on microprojections that provide rapid and efficient systemic delivery in a convenient, needle-free, and pain-free system. Zosano is a fully integrated development company with its own cGMP manufacturing facility. The company is developing products with significant commercial potential both independently and in collaboration with strategic partners. Learn more at http://www.zosanopharma.com.


'/>"/>
SOURCE Zosano Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
2. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
3. Galena Biopharma, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
4. InnoPharma, Inc., Announces U.S. FDA Approval of Acetylcysteine Solution, USP, 20% for Inhalation or Oral Administration
5. Robbins Arroyo LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Hemispherx Biopharma, Inc.
6. Todays Research on PDL BioPharma, Dendreon, Medivation, ACADIA Pharma, and Cell Therapeutics
7. Morning Research on Sequenom, Peregrine Pharma, Onyx Pharma, and Inovio Pharma
8. DFH Pharma, USA Partners with Hetero Group, INDIA to Develop 2nd Generation HIV Maturation Inhibitor Drugs
9. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
10. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
11. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 18, 2017 The ... Food and Drug Administration (FDA) for its release ... and population health decision makers can proactively share ... products as well as emerging therapies awaiting FDA ... mirrors consensus recommendations that AMCP developed during two ...
(Date:1/18/2017)... 2017  EnteroMedics Inc. (NASDAQ: ETRM ... technology to treat obesity, metabolic diseases and other ... underwritten public offering of units for gross proceeds ... and commissions and offering expenses payable by EnteroMedics. ... A Units, priced at a public offering price ...
(Date:1/18/2017)... PORTLAND, Oregon and PUNE, India ... report published by Allied Market Research, titled, "Breast Imaging Technologies ... projects that the global breast imaging technologies market size was ... reach $4,502 million by 2022, growing at a CAGR of ... and Europe together accounted for ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... Sales Focus Inc. (SFI), ... into the US market. , Over the past 20 years SFI has been recognized ... SFI has launched six new clients into the US market. The new clients ...
(Date:1/19/2017)... ... 2017 , ... Each year, the Southeastern Society of Plastic ... of surgeons from over fifteen different countries come together to share and learn ... to breast reconstruction for breast cancer patients, teaching these surgical techniques which ...
(Date:1/18/2017)... ... ... A recent video posting of a new fidget product gathered online momentum as ... stress and anxiety. No one was more surprised than Think Ink Pen founders ... successful Kickstarter campaign raising $67,000 on the popular crowdfunding platform. “We’ve been in ...
(Date:1/18/2017)... ... 18, 2017 , ... Visually learn facts and tips on ... Certain Dri. , Excessive sweating and hyperhidrosis are common conditions that occur in ... explain the seven types of hyperhidrosis. This visual creates awareness about the condition ...
(Date:1/18/2017)... (PRWEB) , ... January 18, ... ... specialty pharmacy industry’s leading journal and most-read publication among specialty pharmacists and ... Medical Center through its Strategic Alliance Partnership (SAP) program, announced Brian Haug, ...
Breaking Medicine News(10 mins):